Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
Molecular Cancer|May 15, 2025
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoringHeng Jiao, Siyun Lin, Jianmin Gu, et al.
Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
JAMA|June 28, 2018
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical TrialJin Li, Shukui Qin, Rui-Hua Xu, et al.
The New England Journal of Medicine|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal CancerKohei Shitara, Elena Elimova, Tianshu Liu, et al.
Oncotargets and Therapy|August 19, 2021
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal CancerShukui Qin, Rui-Hua Xu, Lin Shen, et al.
Future Oncology (London, England)|December 16, 2020
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trialRuihua Xu, Shukui Qin, Weijian Guo, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
The New England Journal of Medicine|February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaYuichiro Doki, Jaffer A Ajani, Ken Kato, et al.
Innovation (Cambridge (Mass.))|July 9, 2026
Chinese consensus on first-line precision therapy for advanced gastric cancerXiaotian Zhang, Weiqi Sheng, Tong Xie, et al.
Pageof 30